logo
GreenFirst Reports Financial Results for the First Quarter of 2025

GreenFirst Reports Financial Results for the First Quarter of 2025

Yahoo14-05-2025

TORONTO, May 14, 2025--(BUSINESS WIRE)--GreenFirst Forest Products Inc. (TSX: GFP) ("GreenFirst" or the "Company") announced results for the first quarter ended March 29, 2025. The Company's interim financial statements ("Financial Statements") and related Management's Discussion and Analysis ("MD&A") for the first quarter ended March 29, 2025 are available on GreenFirst's website at www.greenfirst.ca and on SEDAR+ at www.sedarplus.ca.
Highlights
Q1 2025 net income from continuing operations was $0.9 million or $0.04 earnings per share (diluted), compared to net loss of $26.6 million or $1.39 loss per share (diluted) in Q4 2024. Adjusted EBITDA from continuing operations for Q1 2025 was positive $5.1 million compared to negative $0.9 million in Q4 2024.
Benchmark prices saw increases during the quarter which resulted in an average realized lumber prices of $729/mfbm for Q1 2025 which was higher than the $680/mfbm pricing realized in Q4 2024.
On February 1, 2025, the new U.S. administration issued an executive order imposing new tariffs on imports from Canada, which came into effect on March 4, 2025. These tariffs were subsequently reversed on March 6, 2025. On April 2, 2025, the U.S. administration issued a new executive order imposing a 10% tariff on all imports into the U.S. from all countries, with much higher tariffs applied to certain other goods. However, goods compliant with the USMCA, such as lumber, are exempt from these tariffs. These events contributed to an environment of economic uncertainty during the quarter.
GreenFirst Reports Positive Q1 Results Amid Market Uncertainty
"We are pleased to report Q1 2025 performance with positive EBITDA and net income from continuing operations, despite economic uncertainty and ongoing potential tariffs on lumber exports to the U.S.
While sales volumes and production were down due to market conditions and weather-related disruptions in Ontario, strong lumber prices exceeded expectations and supported the company's positive financial results.
Looking ahead, we remain committed to disciplined capital expenditures and maintaining a strong balance sheet to navigate market volatility and potential headwinds," said Joel Fournier, CEO of GreenFirst.
Financial Highlights
The following selected financial information is from the Company's financial statements and MD&A:
(In thousands of CAD, except per share amounts)
March 29,
December 31,
March 30,
For the quarter ended
2025
2024
2024(4
)
Net sales from continuing operations(3)
$
71,830
$
69,948
$
72,447
Operating earnings (loss) from continuing operations
1,411
(5,415
)
2,666
Net income (loss)
920
(28,029
)
(13,351
)
Net income (loss) from continuing operations
920
(26,647
)
141
Basic earnings (loss) per share
0.04
(1.47
)
(0.75
)
Basic earnings (loss) per share from continuing operations
0.04
(1.39
)
0.01
Diluted earnings (loss) per share
0.04
(1.47
)
(0.75
)
Diluted earnings (loss) per share from continuing operations
0.04
(1.39
)
0.01
Adjusted EBITDA from continuing operations(1)(2)
$
5,060
$
(913
)
$
6,296
(In thousands of CAD)
March 29,
December 31,
As at
2025
2024
Total assets
$
243,518
$
220,466
Total liabilities
96,126
74,850
Total shareholders' equity
$
147,392
$
145,616
1
Adjusted EBITDA is a Non‐GAAP measure and does not have standardized meaning under GAAP or IFRS. As a result, it may not be comparable to information presented by other companies. For an explanation and reconciliation of Adjusted EBITDA to related comparable financial information presented in the Financial Statements prepared in accordance with IFRS, refer to the Non-GAAP Measures section in this MD&A.
2
Non-GAAP Adjusted EBITDA before one-time duties recoveries for the first quarter ended March 29, 2025 was positive $5.1 million compared to positive $6.3 million for the first quarter ended March 30, 2024 and negative $0.9 million for the fourth quarter ended December 31, 2024.
3
Includes net sales to external parties.
4
Certain prior period amounts have been restated as a result of a change in presentation of the Company's Financial Statements for continuing and discontinued operations under IFRS. Please refer to Note 4 - Discontinued Operations, in the Company's Financial Statements for further information.
Net sales were $71.8 million in Q1 2025, an increase of approximately 3% compared to Q4 2024. The increase in net sales was primarily driven by higher realized pricing during the quarter, which offset the impact of lower shipments.
Cost of sales were $62.1 million, a decrease of approximately 9% compared to Q4 2024. The decrease in cost of sales was primarily due to lower shipment volumes during the quarter.
Other Expenses
Duties expense of $5.7 million in the first quarter of 2025 were lower than the fourth quarter of 2024 of $6.2 million due to lower shipments. During both quarters the Company was subject to a combined duty rate of 14.4%.
SG&A expenses were $2.6 million in the first quarter of 2025 compared to $2.8 million in the fourth quarter ended December 31, 2024 which is aligned with the Company's initiative to managing its SG&A.
Liquidity and Borrowings
At March 29, 2025, the Company had $2.5 million in cash on hand and $40.3 million, less $8.6 million for standby letters of credit, of excess availability under its revolving portion of the credit facility. In addition, the Company also had access to $12.0 million remaining under its equipment financing portion of the credit facility. The Company had drawn down $12.0 million under its revolving portion of the credit facility and $13.0 million (net of repayments) under its equipment financing agreement as at March 29, 2025.
Outlook
The economic outlook for the lumber industry reflects a balance of ongoing challenges and emerging opportunities. Macroeconomic concerns are beginning to stabilize, which may support a recovery in lumber demand and pricing. In North America, the housing market is showing signs of recovery after recent volatility. Mortgage rates are expected to ease while price growth moderates in 2025, which should improve affordability for borrowers. This could provide relief to homeowners and support demand in new construction, remodeling, and renovation activity which are all keys factors that are expected to continue driving lumber demand. However, it's hard to say for sure how much mortgage rates will go down and it is also possible they will rise due to the current economic uncertainty.
Structural market dynamics are also contributing to longer-term demand fundamentals. A persistent shortage of housing inventory in the U.S., the aging of the existing housing stock, and demographic-driven demand are likely to support the lumber market both in the near and long term.
In the short term, reduced lumber demand and conservative inventory management are creating supply-side pressures. However, continued production curtailments across several regions including British Columbia, Quebec, and other areas of North America could help stabilize or even support lumber prices in the coming months.
Labour market constraints remain a key challenge for the industry, contributing to higher costs and occasional production disruptions. Inflationary pressures across North America have further increased the cost of critical inputs, placing additional strain on operational efficiency. Staffing challenges and tight wood supply are ongoing risks that could negatively impact production output and margins across the industry. Despite these pressures, continuous improvements in production and processing techniques are driving gains in efficiency and helping reduce costs. Companies with access to capital to invest in modern, efficient equipment are better positioned to enhance long-term competitiveness.
A growing focus on environmental sustainability is also reshaping the industry landscape. Organizations that prioritize sustainable forest management and environmentally responsible operations are increasingly gaining favor among regulators, consumers, and investors. GreenFirst is aligned with this trend, producing high-quality lumber in a safe and responsible manner. We are committed to protecting our employees and the environment while creating long-term value for our stakeholders. Our renewable building materials sequester carbon and represent a natural solution in the global effort to combat climate change.
Nonetheless, downside risks remain. Should broader economic conditions or employment levels weaken significantly, or if interest rates remain elevated for an extended period without sufficient adjustments in housing prices, affordability could remain strained. This scenario could suppress new home construction and, in turn, reduce near-term demand for lumber products.
On February 1, 2025, the new U.S. administration issued an executive order imposing new tariffs on imports from Canada, which came into effect on March 4, 2025. These tariffs were subsequently reversed on March 6, 2025. In parallel, on March 1, 2025, the U.S. administration launched a new trade investigation focused on potential anti-dumping measures targeting imported Canadian lumber. This investigation has contributed to an environment of financial uncertainty for Canadian-based lumber manufacturers.
The actual impact of any current or future tariffs remains unknown and cannot be reasonably estimated at this time. Several factors will influence the outcome, including the effective date and duration of any new trade actions, potential changes in the amount, scope, or nature of the tariffs, and the possibility of countermeasures by the Canadian government. Additionally, any mitigating actions available to the Company or the broader industry may affect the overall impact. We continue to monitor developments closely and assess their potential implications for our operations and financial position.
Reconciliation of Adjusted EBITDA
References to EBITDA in this document are measures of earnings (loss) before interest and finance costs, income taxes, depreciation and amortization, while references to Adjusted EBITDA reflect EBITDA plus other non-operating costs such as impact of valuation changes on the Company's investments, loss on sale of assets and other non-operating losses. Management believes that certain lenders, investors, and analysts use EBITDA and Adjusted EBITDA as a common valuation measurement and to measure the Company's ability to service debt and meet other payment obligations. EBITDA and Adjusted EBITDA are not intended to replace net earnings (loss), or other measures of financial performance and liquidity reported in accordance with GAAP. For more information on non-GAAP measures, please see the Company's MD&A.
(In thousands of CAD)
For the quarter ended
March 29, 2025
December 31, 2024
March 30, 2024(3)
Net income (loss) from continuing operations
$
920
$
(26,647
)
$
141
Adjustments:
Finance costs, net
440
1,082
1,056
Income taxes
51
4,072
1,539
Depreciation and amortization
3,649
4,502
3,630
EBITDA
5,060
(16,991
)
6,366
Gain on sale of assets

16,078
(70
)
Adjusted EBITDA from continuing operations(1)(2)
$
5,060
$
(913
)
$
6,296
1
Adjusted EBITDA is a Non‐GAAP measure and does not have standardized meaning under GAAP or IFRS. As a result, it may not be comparable to information presented by other companies. For an explanation and reconciliation of Adjusted EBITDA to related comparable financial information presented in the Financial Statements prepared in accordance with IFRS, refer to the Non-GAAP Measures section in this MD&A.
2
Non-GAAP Adjusted EBITDA before one-time duties recoveries for the first quarter ended March 29, 2025 was positive $5.1 million compared to positive $6.3 million for the first quarter ended March 30, 2024 and negative $0.9 million for the fourth quarter ended December 31, 2024.
3
Certain prior period amounts have been restated as a result of a change in presentation of the Company's Financial Statements for continuing and discontinued operations under IFRS. Please refer to Note 4 - Discontinued Operations, in the Company's Financial Statements for further information.
Earnings Conference Call
GreenFirst will host a conference call to review the Q1 2025 financial results on Wednesday, March 14, 2025 at 9:00am (Eastern). The live webcast of the earnings conference call can be accessed via web: http://momentum.adobeconnect.com/greenfirst2025/ and via phone: (+1) 416 764 8658 or (+1) 888 886 7786. A replay of the webcast and presentation slides will be available on GreenFirst's website following the conference call.
About GreenFirst
GreenFirst Forest Products is a forest-first business, focused on sustainable forest management and lumber production. The Company owns four sawmills located in rich wood baskets proudly operating over six million hectares of FSC® certified public Ontario forest lands (FSC®-C167905). The Company believes that responsible forest practices, coupled with the long-term green advantage of lumber, provide GreenFirst with significant cyclical and secular advantages in building products.
Forward Looking Information
Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact are forward-looking statements. Forward looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend", "estimate" or the negative of these terms and similar expressions. Forward-looking statements are based on certain assumptions and, while GreenFirst considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. In addition, forward-looking statements necessarily involve known and unknown risks, including those set out in GreenFirst's public disclosure record filed under its profile on www.sedarplus.ca. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. GreenFirst disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
For more information, please visit: www.greenfirst.ca or contact Investor Relations (416) 775 2821
View source version on businesswire.com: https://www.businesswire.com/news/home/20250513254876/en/
Contacts
Investor Relations (416) 775 2821

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

Yahoo

timean hour ago

  • Yahoo

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

Business Wire

time2 hours ago

  • Business Wire

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit

The North American Tariff Backfire
The North American Tariff Backfire

Wall Street Journal

time6 hours ago

  • Wall Street Journal

The North American Tariff Backfire

Canada's Prime Minister Mark Carney has extended a somewhat unusual invitation to Mexico's President Claudia Sheinbaum to attend the Group of Seven meeting later this month in Kananaskis, Alberta. Mexico has been a G-7 guest before, but is far from a regular at the annual confab. The Carney outreach to Ms. Sheinbaum looks like a Canadian attempt to double-team President Trump on trade. It isn't a bad idea. The U.S.-Mexico-Canada Agreement is up for review in 2026, and now's a good time for the smaller partners, who are crucial to American competitiveness globally, to lay down some markers.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store